Pembrolizumab in Combination With Lenvatinib in Patients With Recurrent, Persistent, Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy
Conditions: Recurrent Vulvar Cancer; Persistent Vulvar Cancer; Metastatic Vulva Cancer; Locally Advanced Vulvar Cancer Interventions: Drug: Pembrolizumab; Drug: Lenvatinib Sponsor: AGO Research GmbH Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials